Developer docs
API playgroundTry for free, no card

Search company profiles

Leviticus Cardio

Full company profile

uuid0009lr4

Namestring
Leviticus Cardio
Company typeenum
Private
Founded yearint
2008
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPetah Tikwah, Israel
HQ citystring
Petah Tikwah
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Keyword5 values
wireless cardiac power, ventricular assist devices, transcutaneous energy transfer, medical device technology, cardiac assist systems
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Wireless Power Systems for Cardiac Assist Devices
Social media profiles1 record
Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Leviticus Cardio is developing an inherently robust, unique wireless system designed to power cardiac assist devices such as left ventricular assist devices (LVADs) without the need for a percutaneous driveline cable. The system uses transcutaneous energy transfer to deliver power wirelessly across the skin, intended for integration by medical device manufacturers and use by advanced heart failure patients.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Wireless Power System for Cardiac Assist Devices
CategoryCardiac Assist Device Power Systems
Description

An inherently robust, unique wireless system developed by Leviticus Cardio to provide transcutaneous power to ventricular assist devices, eliminating the need for a percutaneous driveline cable. Targeted at medical device OEMs developing LVADs and at advanced heart failure patients who require mechanical circulatory support.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers2 records
TypeBroad incumbent
2Abbott
TypeBroad incumbent
Description

Abbott's HeartMate 3 is the leading implanted LVAD and the most likely partner/integrator for a wireless power accessory. Comparable as the dominant incumbent in the same mechanical circulatory support category.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Leviticus Cardio

Wireless Power Systems for Cardiac Assist Devicesleviticus-cardio.com

Leviticus Cardio firmographics

Firmographics
Name
Leviticus Cardio
Website
https://leviticus-cardio.com
Company type
Private
Founded year
2008
Headcount range
1–10 employees
Ownership category
akta.pro rank

Where Leviticus Cardio is headquartered

Location

Headquarters

HQ city
Petah Tikwah
HQ country
Israel
HQ region
Middle East

Markets served

Leviticus Cardio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Leviticus Cardio product offering

Product offering

Core offering

Leviticus Cardio is developing an inherently robust, unique wireless system designed to power cardiac assist devices such as left ventricular assist devices (LVADs) without the need for a percutaneous driveline cable. The system uses transcutaneous energy transfer to deliver power wirelessly across the skin, intended for integration by medical device manufacturers and use by advanced heart failure patients.

Differentiator

Problem solved

Functional benefit

Products and services

  • Wireless Power System for Cardiac Assist Devices An inherently robust, unique wireless system developed by Leviticus Cardio to provide transcutaneous power to ventricular assist devices, eliminating the need for a percutaneous driveline cable. Targeted at medical device OEMs developing LVADs and at advanced heart failure patients who require mechanical circulatory support.

Companies that use Leviticus Cardio

Customer profile

Ideal customer profiles2 records

Leviticus Cardio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Leviticus Cardio partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights2 records

Leviticus Cardio competitors and assessment

Company assessment

Broad incumbents

  • Medtronic:
  • Abbott: Abbott's HeartMate 3 is the leading implanted LVAD and the most likely partner/integrator for a wireless power accessory. Comparable as the dominant incumbent in the same mechanical circulatory support category.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Leviticus Cardio social profiles

Digital presence

Leviticus Cardio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Leviticus Cardio leadership team

Management profile

Number of profiles

Profiles1 record

Leviticus Cardio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Leviticus Cardio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Leviticus Cardio

What does Leviticus Cardio do?

Leviticus Cardio is developing an inherently robust, unique wireless system designed to power cardiac assist devices such as left ventricular assist devices (LVADs) without the need for a percutaneous driveline cable. The system uses transcutaneous energy transfer to deliver power wirelessly across the skin, intended for integration by medical device manufacturers and use by advanced heart failure patients.

When was Leviticus Cardio founded?

Leviticus Cardio was founded in 2008. It employs 1 to 10 people.

Where is Leviticus Cardio based?

Leviticus Cardio is headquartered in Petah Tikwah, Israel, in the Middle East region.

Who are Leviticus Cardio's main competitors?

Broad incumbents on record are Medtronic and Abbott.

Does Leviticus Cardio have an API?

No public API is recorded for Leviticus Cardio.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireBreakthrough in Device Therapy for Patients with Late-Stage Heart DiseaseCalon Cardio-Technology Ltd and Leviticus Cardio Ltd have successfully completed a 60-day in-vivo pre-clinical study of a fully implantable ventricular assist device (FiVAD) that combines both companies' technologies, eliminating the need for external power cables that have traditionally limited VAD therapy. The study was conducted at the Catholic University of Leuven in Belgium and demonstrated that patients can go a full day without any external connections, with recharging accomplished simply by wearing a light belt overnight. The companies stated the breakthrough could make VAD therapy a routine treatment option and potentially supersede cardiac transplant as the preferred intervention for advanced heart failure patients.PR NewswireLeviticus Cardio Appoints Prof. Nir Uriel to its Scientific Advisory BoardLeviticus Cardio announced the appointment of Prof. Nir Uriel to its Scientific Advisory Board to help promote the company's wireless solution for Left Ventricular Assist Device (LVAD) patients. Prof. Uriel is a leading expert in heart failure, mechanical circulatory support, and heart transplantation, serving as Director at UChicago Medicine and past Chair of the Mechanical Circulatory Support Council. The company's FiVAD™ technology uses wireless power transfer combined with existing VAD systems to address driveline infection, a key limitation in current LVAD technology.PR NewswireLeviticus Cardio Appoints Prof. Mandeep R. Mehra to Its Scientific Advisory BoardLeviticus Cardio announced the appointment of Prof. Mandeep R. Mehra to its Scientific Advisory Board, leveraging his expertise in advanced heart failure and cardiac transplantation. This strategic move aims to provide guidance on developing fully internalized wireless solutions for Left Ventricular Assist Devices (LVADs). The company's FiVAD technology utilizes wireless power transfer to charge an internal battery, offering a hybrid solution for chronic heart failure patients.News-MedicalLeviticus Cardio and Jarvik Heart reveal novel wireless heart pump systemLeviticus Cardio and Jarvik Heart unveiled a fully implanted wireless heart pump system, FIVAD, after its first human implant in Astana, Kazakhstan, in December. The system uses patented Coplanar Energy Transfer to power a Jarvik 2000 pump, allowing patients to walk without a driveline for up to 8 hours daily. The patient has been discharged and is leading a normal life.PR NewswireLeviticus Cardio et Jarvik Heart dévoilent un système de pompe cardiaque sans fil révolutionnaireA revolutionary fully implanted ventricular assist device (FIVAD) was unveiled publicly after the successful first human implantation in December at the National Research Cardiac Surgery Center in Astana, Kazakhstan, with the patient discharged and returning to normal life. The FIVAD combines Leviticus Cardio's wireless coplanar energy transfer technology with Jarvik Heart's Jarvik 2000 cardiac pump, enabling patients to move freely for up to 8 hours daily without external cables that cause infections in over 20% of conventional cases. Leviticus Cardio and Jarvik Heart jointly announced the system as a breakthrough for severe heart failure patients, expressing hope this successful operation will be the first of many.PR NewswireLeviticus Cardio und Jarvik enthüllen bahnbrechendes kabelloses HerzpumpensystemA fully implanted wireless ventricular assist device (FIVAD) was successfully implanted in a patient at the National Research Center for Cardiac Surgery in Astana, Kazakhstan in December 2018, with the patient discharged and resuming normal life. The system, developed by Israeli medtech company Leviticus Cardio using its proprietary Coplanar Energy Transfer wireless technology, incorporates a Jarvik 2000 pump from Jarvik Heart, Inc. and allows patients to move without physical constraints for up to eight hours daily, addressing infection risks associated with percutaneous cables in conventional VADs. The breakthrough was unveiled at a press conference attended by leading cardiologists and heart surgeons from Harvard Medical School, University of Chicago, and European institutions, with the procedure described as exceeding surgical expectations.PR NewswireLeviticus Cardio & Jarvik Heart Unveil Groundbreaking Wireless Heart Pump SystemLeviticus Cardio and Jarvik Heart announced the successful first human implantation of FIVAD (Fully Implanted Ventricular Assist Device), a wireless heart pump system, at the National Research Center for Cardiac Surgery in Astana, Kazakhstan in December 2018, with the patient discharged and resuming normal life. The FIVAD system uses patented Coplanar Energy Transfer technology to wirelessly power a Jarvik 2000 pump, freeing patients from external wires for up to 8 hours daily and reducing infection risks associated with traditional drivelines. Both companies CEOs jointly stated the technology represents a game-changing advancement for severe heart failure patients, with plans to expand the procedure to additional patients.PR NewswireLeviticus Cardio and Jarvik Heart Awarded R&D Grant From the Prestigious BIRD FoundationLeviticus Cardio and Jarvik Heart have been awarded a $950,000 grant from the Israel-U.S. Binational Industrial Research and Development (BIRD) Foundation to fund development of a fully implanted wireless ventricular assist device (VAD) system. The funding will support the first phase of the $2.9 million project, which is designed to advance toward clinical regulatory trials for the hybrid system combining Jarvik Heart's pump with Leviticus' coplanar energy transfer technology. The grant follows successful long-term animal trials spanning six months.PR NewswireLeviticus Cardio Announces Success of Groundbreaking Six Month Chronic Animal StudyLeviticus Cardio announced the successful completion of a 180-day preclinical chronic animal study evaluating its transcutaneous Coplanar Energy Transfer (CET) technology in combination with a Jarvik Heart ventricular assist device, conducted at the Catholic University of Leuven in Belgium. The company has raised additional funds to proceed with first-in-human trials following this milestone, which represents a significant step toward wireless VAD systems for heart failure patients.PR NewswireLeviticus Cardio Announces Successful Completion of Third Chronic Animal StudyLeviticus Cardio announced the successful completion of a 90-day preclinical chronic animal study evaluating its transcutaneous Coplanar Energy Transfer (CET) wireless technology in combination with Jarvik Heart's Jarvik 2000 left ventricular assist device. The trial was conducted at Catholic University of Leuven's animal facility in Belgium and marked the third successful chronic trial of the technology. The positive results pave the way for first-in-human trials expected within months, representing a significant milestone for the wireless LVAD system.